Leonardo Lucantoni

Leonardo Lucantoni

Auto-generated profile, based on publicly available information

Leonardo Lucantoni

Discovery Biology, Griffith University, Brisbane Innovation Park, Don Young Road, Nathan 4111, Queensland, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KCKatharine A. Collins
Katharine A. Collins
CWClaire Y.T. Wang
Claire Y.T. Wang
MAMatthew Adams
Matthew Adams
HMHayley Mitchell
Hayley Mitchell
GRGreg J. Robinson
Greg J. Robinson
JMJames S. McCarthy
James S. McCarthy
BACKGROUND. Interventions that interrupt Plasmodium vivax transmission or eliminate dormant P. vivax liver-stage parasites will be essential for malaria elimination. Development of these interventions has been hindered by the lack of P. vivax in vitro culture and could be accelerated by a safe and reproducible clinical model in malaria-naive individuals. METHODS. Healthy, malaria-naive adults were enrolled in 2 studies to assess the safety, infectivity, and transmissibility of a new P. vivax isolate. Participants (Study 1, n = 2; Study 2, n = 24) were inoculated with P. vivax–infected red blood cells to initiate infection, and were treated with artemether-lumefantrine (Study 1) or chloroquine (Study 2). Primary endpoints were safety and infectivity of the new isolate. In Study 2, transmission to mosquitoes was also evaluated using mosquito feeding assays, and sporozoite viability was assessed using in vitro cultured hepatocytes. RESULTS. Parasitemia and gametocytemia developed in all participants and was cleared by antimalarial treatment. Adverse events were mostly mild or moderate and none were serious. Sixty-nine percent of participants (11/16) were infectious to Anopheles mosquitoes at peak gametocytemia. Mosquito infection rates reached 97% following membrane feeding with gametocyte-enriched blood, and sporozoites developed into liver-stage schizonts in culture. CONCLUSION. We have demonstrated the safe, reproducible, and efficient transmission of P. vivax gametocytes from humans to mosquitoes, and have established an experimental model that will accelerate the development of interventions targeting multiple stages of the P. vivax life cycle. TRIAL REGISTRATION. ACTRN12614000930684 and ACTRN12616000174482. FUNDING. (Australian) National Health and Medical Research Council Program Grant 1132975 (Study 1). Bill and Melinda Gates Foundation (OPP1111147) (Study 2).

26 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BLBENOIT LALEU
BENOIT LALEU
YAYuichiro Akao
Yuichiro Akao
AOAtsuko Ochida
Atsuko Ochida
SDSandra Duffy
Sandra Duffy
LLLeonardo Lucantoni
Leonardo Lucantoni
MKMasahiro Kamaura
Masahiro Kamaura
A phenotypic high-throughput screen allowed discovery of quinazolinone-2-carboxamide derivatives as a novel antimalarial scaffold. Structure–activity relationship studies led to identification of a potent inhibitor 19f, 95-fold more potent than the original hit compound, active against laboratory-resistant strains of malaria. Profiling of 19f suggested a fast in vitro killing profile. In vivo activity in a murine model of human malaria in a dose-dependent manner constitutes a concomitant benefit.

21 January 2020 in Journal of Natural Products
Verified
Journal Article
Closed access
GKGuy Kleks
Guy Kleks
SDSandra Duffy
Sandra Duffy
LLLeonardo Lucantoni
Leonardo Lucantoni
VAVicky M. Avery
Vicky M. Avery
ACAnthony Carroll
Anthony Carroll

30 April 2021 in ACS Infectious Diseases
Verified
Journal Article
Open access
MOMasanori Okaniwa
Masanori Okaniwa
ASAkira Shibata
Akira Shibata
AOAtsuko Ochida
Atsuko Ochida
YAYuichiro Akao
Yuichiro Akao
KWKaren L. White
Karen L. White
BLBENOIT LALEU
BENOIT LALEU
Prolyl-tRNA synthetase (PRS) is a clinically validated antimalarial target. Screening of a set of PRS ATP-site binders, initially designed for human indications, led to identification of 1-(pyridin-4-yl)pyrrolidin-2-one derivatives representing a novel antimalarial scaffold. Evidence designates cytoplasmic PRS as the drug target. The frontrunner 1 and its active enantiomer 1-S exhibited low-double-digit nanomolar activity against resistant Plasmodium falciparum (Pf) laboratory strains and development of liver schizonts. No cross-resistance with strains resistant to other known antimalarials was noted. In addition, a similar level of growth inhibition was observed against clinical field isolates of Pf and P. vivax. The slow killing profile and the relative high propensity to develop resistance in vitro (minimum inoculum resistance of 8 × 105 parasites at a selection pressure of 3 × IC50) constitute unfavorable features for treatment of malaria. However, potent blood stage and antischizontal activity are compelling for causal prophylaxis which does not require fast onset of action. Achieving sufficient on-target selectivity appears to be particularly challenging and should be the primary focus during the next steps of optimization of this chemical series. Encouraging preliminary off-target profile and oral efficacy in a humanized murine model of Pf malaria allowed us to conclude that 1-(pyridin-4-yl)pyrrolidin-2-one derivatives represent a promising starting point for the identification of novel antimalarial prophylactic agents that selectively target Plasmodium PRS.

3 July 2018 in Journal of Natural Products
Verified
Journal Article
Closed access
DPDayani Senadeera Sarath Parakumge
Dayani Senadeera Sarath Parakumge
LLLeonardo Lucantoni
Leonardo Lucantoni
SDSandra Duffy
Sandra Duffy
VAVicky Avery
Vicky Avery
ACAnthony Carroll
Anthony Carroll

31 July 2018 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
NBNicholas M. Butler
Nicholas M. Butler
RHRudi Hendra
Rudi Hendra
JBJohn B. Bremner
John B. Bremner
AWAnthony C. Willis
Anthony C. Willis
LLLeonardo Lucantoni
Leonardo Lucantoni
PKPaul Keller
Paul Keller
The base-initiated alkylation of the abundant natural dye indigo 1 with ring-strained electrophiles results in the unprecedented, one-pot synthesis of functionalised dihydropyrazino[1,2-a:4,3-a′]diindoles, dihydroepoxy[1,5]oxazocino[5,4-a:3,2-b′]diindoles, and dihydrodiazepino[1,2-a:4,3-a′]diindoles, resulting from intramolecular ring opening-expansion cyclisation processes of their parent oxiranes and aziridines. Regiochemical and stereochemical aspects of the reactions are reported together with integrated mechanistic proposals. This new indigo cascade chemistry should have broad applicability in the synthesis of chemical architectures, not readily-accessible by other means. The three-step synthesis of the useful synthetic precursor (R)-2-(chloromethyl)-1-tosylaziridine 14 is also described. Initial biological activity investigations into these new 2,2′-dindolyl-based heterocyclic derivatives revealed potent, selective antiplasmodial activity in vitro for several isolated structures, with IC50 values as low as 76.6 nM for (±)-8, while demonstrating low human cell toxicity.